Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling.

Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C.

Oncogene. 2020 Jan;39(3):574-586. doi: 10.1038/s41388-019-0964-6. Epub 2019 Sep 10.

PMID:
31506605
2.

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.

Huang CP, Chen J, Chen CC, Liu G, Zhang Y, Messing E, Yeh S, Chang C.

J Exp Clin Cancer Res. 2019 Jun 24;38(1):275. doi: 10.1186/s13046-019-1258-0.

3.

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.

Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, Xu W, Niu Y, Cheng L, Maity SN, Jiang R, Chang C.

Nat Commun. 2019 Jun 12;10(1):2571. doi: 10.1038/s41467-019-09784-9.

4.

The Protective Roles of Estrogen Receptor β in Renal Calcium Oxalate Crystal Formation via Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury.

Zhu W, Zhao Z, Chou FJ, Zuo L, Liu T, Bushinsky D, Chang C, Zeng G, Yeh S.

Oxid Med Cell Longev. 2019 Apr 17;2019:5305014. doi: 10.1155/2019/5305014. eCollection 2019.

5.

Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals.

Zhu W, Zhao Z, Chou F, Zuo L, Liu T, Yeh S, Bushinsky D, Zeng G, Chang C.

Cell Death Dis. 2019 Mar 20;10(4):275. doi: 10.1038/s41419-019-1358-y.

6.

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.

EBioMedicine. 2019 Feb;40:504-516. doi: 10.1016/j.ebiom.2018.12.050. Epub 2019 Jan 26.

7.

Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals.

Ou Z, Wang Y, Chen J, Tao L, Zuo L, Sahasrabudhe D, Joseph J, Wang L, Yeh S.

Exp Mol Med. 2018 Nov 20;50(11):152. doi: 10.1038/s12276-018-0155-5.

8.

Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.

Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, Gong L, Chang C.

Cancer Lett. 2019 Mar 1;444:175-187. doi: 10.1016/j.canlet.2018.11.004. Epub 2018 Nov 15.

PMID:
30448543
9.

Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.

Yu W, Ding J, He M, Chen Y, Wang R, Han Z, Xing EZ, Zhang C, Yeh S.

Oncogene. 2019 Feb;38(8):1225-1238. doi: 10.1038/s41388-018-0463-1. Epub 2018 Sep 24.

PMID:
30250297
10.

Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.

Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C.

Cancer Lett. 2019 Mar 1;444:35-44. doi: 10.1016/j.canlet.2018.09.025. Epub 2018 Sep 21.

PMID:
30248372
11.

ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.

Niu Y, Guo C, Wen S, Tian J, Luo J, Wang K, Tian H, Yeh S, Chang C.

Cancer Lett. 2018 Dec 28;439:47-55. doi: 10.1016/j.canlet.2018.09.020. Epub 2018 Sep 15. Review.

PMID:
30227222
12.

Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.

Song W, He D, Chen Y, Yeh CR, Hsu I, Huang Q, Zhang X, Chang LS, Zuo L, Chen J, Doersch KM, Chang C, Li L, Yeh S.

Mol Oncol. 2018 Dec;12(12):2055-2071. doi: 10.1002/1878-0261.12377. Epub 2018 Oct 30.

13.

TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals.

Bai J, Yeh S, Qiu X, Hu L, Zeng J, Cai Y, Zuo L, Li G, Yang G, Chang C.

Oncogene. 2018 Nov;37(44):5901-5912. doi: 10.1038/s41388-018-0269-1. Epub 2018 Jul 4.

PMID:
29973687
14.

Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.

Ding J, Yeh CR, Sun Y, Lin C, Chou J, Ou Z, Chang C, Qi J, Yeh S.

Oncogene. 2018 Sep;37(37):5037-5053. doi: 10.1038/s41388-018-0175-6. Epub 2018 May 23.

PMID:
29789714
15.

Estrogen receptors orchestrate cell growth and differentiation to facilitate liver regeneration.

Kao TL, Kuan YP, Cheng WC, Chang WC, Jeng LB, Yeh S, Ma WL.

Theranostics. 2018 Apr 9;8(10):2672-2682. doi: 10.7150/thno.23624. eCollection 2018.

16.

Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals.

Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Zuo L, Guancial EA, Messing EM, Chang C, Yeh S.

Cancer Lett. 2018 Aug 28;430:215-223. doi: 10.1016/j.canlet.2018.03.045. Epub 2018 Apr 22.

PMID:
29684419
17.

ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma.

Han Z, Zhang Y, Sun Y, Chen J, Chang C, Wang X, Yeh S.

Cancer Res. 2018 May 15;78(10):2550-2563. doi: 10.1158/0008-5472.CAN-17-1575. Epub 2018 Feb 28.

18.

Estrogen-Estrogen Receptor α Signaling Facilitates Bilirubin Metabolism in Regenerating Liver Through Regulating Cytochrome P450 2A6 Expression.

Kao TL, Chen YL, Kuan YP, Chang WC, Ho YC, Yeh S, Jeng LB, Ma WL.

Cell Transplant. 2017 Nov;26(11):1822-1829. doi: 10.1177/0963689717738258.

19.

Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.

Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C.

Cancer Lett. 2018 Mar 28;417:182-191. doi: 10.1016/j.canlet.2017.11.038. Epub 2018 Jan 17.

PMID:
29203251
20.

Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.

Chen J, Li L, Yang Z, Luo J, Yeh S, Chang C.

Cancer Lett. 2017 Nov 1;408:155-163. doi: 10.1016/j.canlet.2017.08.014. Epub 2017 Aug 18.

PMID:
28826721

Supplemental Content

Loading ...
Support Center